ACTIONS OF MELANOCORTIN AGONISTS IN OBESE PRIMATES

黑皮质素激动剂对肥胖灵长类动物的作用

• 批准号: 8357859
• 负责人: KEVIN L GROVE
• 金额: $ 7.28万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357859
• 关键词: Adverse effects; Agonist; Animals; Blood Pressure; Body Weight; Cardiovascular system; Clinical Research; Drug Delivery Systems; Drug Formulations; Fishes; Funding; Grant; Heart Rate; Human; Manuscripts; Melanocortin 4 Receptor; Monkeys; National Center for Research Resources; Obesity; Primates; Principal Investigator; Research; Research Design; Research Infrastructure; Resources; Source; System; Therapeutic; United States National Institutes of Health; Writing; analog; blood glucose regulation; cost; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The MC4 receptor is considered to be one of the most potent anorexigenic systems and thus a highly sought after drug target. This system appears to be conserved across many species from fish to humans. However, this target also has great potential for cardiovascular side effects. The purpose of this study is to investigate a novel MC4 analog to 1) validate the efficacy of this compound and show that it can have potent effects body weight and glucose homeostasis in obese prediabetic monkeys; and 2) to investigate potential cardiovascular side effects and therapeutic window. The results from these previous studies have been written into a manuscript that we expect to submit soon. These new studies are designed to further clinical studies to identify formulations that have the highest efficacy with no significant cardiovascular complications (blood pressure or heart rate). Furthermore, these studies used animals from the Obese NHP Resource.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 MC4受体被认为是最有效的厌食症系统之一，因此是备受追捧的药物靶标。 该系统似乎是从鱼到人类的许多物种中保守的。 但是，该目标也具有心血管副作用的巨大潜力。 这项研究的目的是研究一种新型的MC4类似物1）验证该化合物的功效，并表明它可以在肥胖的糖尿病前猴中具有有效的体重和葡萄糖稳态； 2）研究潜在的心血管副作用和治疗窗口。 这些先前研究的结果已将其写入我们希望很快提交的手稿中。这些新研究旨在进一步的临床研究，以识别具有最高功效的表述，没有明显的心血管并发症（血压或心率）。 此外，这些研究还使用了肥胖NHP资源中的动物。